Levi & Korsinsky announces it has commenced an investigation of Otonomy, Inc. (“Otonomy” or the “Company”) (NASDAQ: OTIC) concerning possible violations of federal securities laws.

On August 30, 2017, Otonomy announced that its Phase 3 clinical trial of OTIVIDEX missed its primary endpoint. The Company also announced an immediate suspension of all development activities for OTIVIDEX. David A. Weber, President and CEO of Otonomy, said “We are greatly disappointed by these results, and surprised by both the higher placebo response and lower OTIVIDEX improvement than observed in our previous trials.” Following this news, shares of Otonomy were down more than 80% on intraday trading on August 30, 2017. To obtain additional information, go to:

http://www.zlkdocs.com/OTIC-Info-Request-Form-6068

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.